KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
2 patients with KIT D816V positive SM, 1 with AdvSM and 1 with ISM, both of whom received KIT-targeted therapies.
I · Intervention 중재 / 시술
KIT-targeted therapies
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
추출되지 않음
Systemic mastocytosis (SM) is a rare hematological neoplasm driven by the KIT D816V mutation in up to 95% of cases.
APA
Reiter A, Rossignol J, et al. (2026). KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.. The journal of allergy and clinical immunology. In practice, 14(1), 44-52. https://doi.org/10.1016/j.jaip.2025.10.034
MLA
Reiter A, et al.. "KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.." The journal of allergy and clinical immunology. In practice, vol. 14, no. 1, 2026, pp. 44-52.
PMID
41187902 ↗
Abstract 한글 요약
Systemic mastocytosis (SM) is a rare hematological neoplasm driven by the KIT D816V mutation in up to 95% of cases. SM is classified into nonadvanced SM-comprising indolent SM (ISM), bone marrow (BM) mastocytosis, and smoldering SM-and advanced SM (AdvSM), with the subtypes aggressive SM, SM with an associated hematological neoplasm (SM-AHN according to the World Health Organization), and mast cell (MC) leukemia. Clinical presentations are heterogeneous, and careful evaluation of clinical and laboratory parameters is required to plan patient management. Here we discuss the diagnosis and treatment of 2 patients with KIT D816V positive SM, 1 with AdvSM and 1 with ISM, both of whom received KIT-targeted therapies. In addition to clinical presentations caused by a combination of MC mediator symptoms and consequences from MC infiltration of different organ systems, the diagnostic workup included qualitative and quantitative assessment of variably affected key parameters from (1) peripheral blood (eg, blood counts, serum tryptase, and other serum markers; variant allele frequency [VAF] of KIT D816V; and additional somatic mutations); (2) BM MC infiltration, KIT D816V VAF, presence/absence of an AHN/associated myeloid neoplasm, and cytogenetic analysis; and (3) organ infiltration/dysfunction (primarily affecting skin, bone/BM, and visceral organs).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.